An official website of the United States government Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Biologic License Application (BLA): 761079
Company: BIOMARIN PHARM

Medication Guide

REMS

Products on BLA 761079

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
PALYNZIQ	PEGVALIASE-PQPZ	2.5MG/O.5ML	INJECTABLE;INJECTION	Prescription	None	No	No
PALYNZIQ	PEGVALIASE-PQPZ	10MG/0.5ML	INJECTABLE;INJECTION	Prescription	None	No	No
PALYNZIQ	PEGVALIASE-PQPZ	20MG/ML	INJECTABLE;INJECTION	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for BLA 761079

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
05/24/2018	ORIG-1	Approval		N/A; Orphan	Label (PDF) Letter (PDF) Review		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/761079Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761079Orig1s000TOC.html

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
11/20/2025	SUPPL-34	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761079s034lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/761079Orig1s034ltr.pdf
02/27/2026	SUPPL-31	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761079s031lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761079Orig1s031correctedltr.pdf
12/09/2023	SUPPL-25	Supplement	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/761079Orig1s025ltr.pdf
11/20/2020	SUPPL-10	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761079s010lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761079Orig1s010ltr.pdf
10/06/2020	SUPPL-7	Supplement	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761079Orig1s005,s006,s007ltr.pdf
10/06/2020	SUPPL-6	Supplement	Letter (PDF)	Label is not available on this site.	https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761079Orig1s005,s006,s007ltr.pdf
10/06/2020	SUPPL-5	Supplement	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761079s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761079Orig1s005,s006,s007ltr.pdf

Labels for BLA 761079

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
02/27/2026	SUPPL-31	Efficacy-New Patient Population	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761079s031lbl.pdf
11/20/2025	SUPPL-34	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761079s034lbl.pdf
11/20/2025	SUPPL-34	Labeling-Medication Guide	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761079s034lbl.pdf
11/20/2020	SUPPL-10	Labeling-Package Insert	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761079s010lbl.pdf
10/06/2020	SUPPL-5	Efficacy-Labeling Change With Clinical Data	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761079s005lbl.pdf
05/24/2018	ORIG-1	Approval	Label (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761079s000lbl.pdf

Top